Mass. Medicaid Leukotriene Blocker Limitation Seeks To Curb Allergy Use
Executive Summary
Oral leukotriene blocker prescriptions will require prior authorization in the Massachusetts Medicaid program in an effort to curb use of the products for allergic rhinitis
You may also be interested in...
Mass. Medicaid To Establish Quantity Limit For Short-Acting Beta-2 Agonists
Massachusetts Medicaid will establish a quantity limit for short-acting beta-2 agonists to encourage physicians to alter "inadequate" anti-inflammatory therapy
Mass. Medicaid To Establish Quantity Limit For Short-Acting Beta-2 Agonists
Massachusetts Medicaid will establish a quantity limit for short-acting beta-2 agonists to encourage physicians to alter "inadequate" anti-inflammatory therapy
Merck Singulair Formulary Status Stable; Restricted Use In Subset Of Plans
Merck's Singulair allergic rhinitis indication is gaining formulary status in the majority of managed care accounts despite the availability of OTC Claritin, the company told investors April 21